DUALITYBIO-B (09606) announced that its Board of Directors intends to utilize the general mandate granted by shareholders at the Annual General Meeting held on June 20, 2025, to repurchase the company's shares on the open market at appropriate times. The share repurchase program plans to utilize up to US$40 million for share buybacks. The company will fund the repurchases using its internal resources and intends to hold the shares bought back under the program as treasury stock. The Board believes the current trading price of the shares does not reflect their intrinsic value and the company's business prospects, presenting a favorable opportunity for the company to repurchase shares. The share repurchase program reflects the Board and management team's confidence in the company's long-term strategy and growth. The Board considers the share repurchase program to be in the overall best interests of the company and its shareholders. Additionally, based on confidence in the future development prospects of the group and recognition of the company's long-term investment value, Dr. Zhu Zhongyuan, the company's founder, Chairman of the Board, Executive Director, and Chief Executive Officer, intends to use personal funds to purchase additional company shares on the open market, with a total amount not exceeding US$5 million, in compliance with listing rules and other applicable laws and regulations.